SCHEMBL660681

SCHEMBL660681

COc1ccc(C(=O)OCCNC(=O)C2=CN(CC(=O)Nc3ccccc3)C=CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
MAPK1 P28482 2/20 0.43
HPGD P15428 1/20 0.43
POLB P06746 3/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
KCNA5 P22460 1/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALDH1A1 P00352 6/20 0.40
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NPC1 O15118 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660292 0.79 ALDH1A1 (0.43) SMN1; SMN2MEN1KMT2AALDH1A1LMNA
SCHEMBL659989 0.77 MEN1 (0.44) SMN1; SMN2MAPK1HPGDPOLBMAPT
SCHEMBL287234 0.74 ALDH1A1 (0.47) SMN1; SMN2HPGDMAPTALDH1A1LMNA
SCHEMBL287827 0.72 ALDH1A1 (0.41) SMN1; SMN2MEN1KMT2AALDH1A1LMNA
SCHEMBL12088287 0.69 GAA (0.53) SMN1; SMN2POLBMAPTMEN1KMT2A
SCHEMBL659675 0.68 NPSR1 (0.44) SMN1; SMN2MAPK1HPGDMAPTMEN1
SCHEMBL286819 0.67 MAPT (0.43) SMN1; SMN2POLBMAPTMEN1KMT2A
SCHEMBL660962 0.65 KMT2A (0.41) SMN1; SMN2HPGDPOLBMAPTMEN1
SCHEMBL8987146 0.63 KMT2A (0.74) SMN1; SMN2POLBCTDSP1MAPTMEN1
SCHEMBL28347341 0.63 SMN1; SMN2 (0.56) SMN1; SMN2MAPK1HPGDPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459175-A Piperidine derivatives for the treatment of diabetes TORRENT PHARMACEUTICALS LTD 2012-05-16 CN claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
CN-102459175-A Piperidine derivatives for the treatment of diabetes TORRENT PHARMACEUTICALS LTD 2012-05-16 CN disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT SMN1; SMN2 640/4885MAPK1 1750/4885HPGD 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.